Saga Bio

Saga Bio, Inc. is a translational immunology and immunodiagnostics company focused on the development of rapid diagnostic tools and therapeutic interventions for inflammatory diseases. Founded as a spinout from Yale University, the company is primarily developing point-of-care (POC) diagnostic platforms for Kawasaki Disease (KD), utilizing biomarkers such as soluble tumor necrosis factor receptor 2 (sTNFR2) and vascular chemokines to differentiate KD from other pediatric febrile illnesses. In addition to its diagnostic portfolio, Saga Bio is advancing a pipeline of humanized therapeutic monoclonal antibodies aimed at treating broader inflammatory conditions. The company is headquartered in Branford, Connecticut, and leverages proprietary insights into vascular immunology and disease pathogenesis.